CHG

CLEOPATRA HOSPITALS GROUP

Transforming Healthcare in Egypt

Investor Presentation H1 2026

Disclaimer

This presentation contains forward-looking statements, including, but not limited to, statements concerning expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, plans or goals relating to financial position and future operations and development. Although Cleopatra Hospitals Group believes that the expectations and opinions reflected in such forward looking statements are reasonable, no assurance can be given that such expectations and opinions will prove to have been correct. By their nature, these forward-looking statements are subject to a number of known and unknown risks, uncertainties and contingencies, and actual results and events could differ materially from those currently being anticipated as reflected in such statements. Important factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements, certain of which are beyond our control, include, among other things: business integration risk; compliance risk; recruitment and retention of skilled medical practitioners risk: clinical risk; concentration of revenue; currency and macroeconomic; information technology and operational risk; regional tensions and political risk; and other key factors that we have indicated could adversely affect our business and financial performance, which are contained elsewhere in this document and in our past and future filings and reports. No part of these results constitutes, or shall be taken to constitute, an invitation or inducement to invest in Cleopatra Hospital Group or any other entity and must not be relied upon in any way in connection with any investment decision. Cleopatra Hospital Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required. Nothing in this document should be construed as a profit forecast.

CONTENTS



Cleopatra Hospitals Group Highlights

CHG Mission, Vision and Values

Our Mission

- A Patient-First Approach to Healthcare
  - Delivering Leading Quality Services
  - Ensuring Safety of all Stakeholders
  - Growing Beds Supply & Expanding their Distribution
  - Improving Quality of Lives Everyday

Our Vision

- Sustainable Growth & Cross-Asset Collaboration
  - Positive Impact to all Stakeholders
  - Transformation of Healthcare Services Provision
  - Fostering Overall Market Growth
- Distinctive Workplace
  - Empowering Our Team
  - Consistent Investing in Training & Technology
  - Preferred Healthcare Employer

Our Approach

- Innovation & Investment
  - Fueling Technology & Infrastructure
  - Regulatory & Accreditor Bodies Alignment
  - Future-Proofing Healthcare Sector Growth
- Synergy & Quality Focus
  - Amplifying Stakeholder Gains
  - Elevating & Standardizing Service Quality & Safety
  - Integration Leveraging Scale, Access, & Cost Synergies

Broad Network Across Greater Cairo and Beyond, Penetrating Underserved Regions

Leveraging a growing footprint, CHG continues to penetrate new segments of the population and provide high quality care to underserved regions across Greater Cairo



CLEOPATRA HOSPITAL
CLEOPATRA HOSPITALS GROUP
(100% ownership)

CAIRO SPECIALISED HOSPITAL
CLEOPATRA HOSPITALS GROUP
(57% ownership)

NILE BADRAWI HOSPITAL
CLEOPATRA HOSPITALS GROUP
(99.9% ownership)

AL SHOROUK HOSPITAL
CLEOPATRA HOSPITALS GROUP
(100% ownership)

ELKATIB HOSPITAL
CLEOPATRA HOSPITALS GROUP
(100% ownership)

CLEOPATRA OCTOBER
CLEOPATRA HOSPITALS GROUP
(Revenue Share Agreement)

CLEOPATRA El TAGAMOA
CLEOPATRA HOSPITALS GROUP
(Revenue Share Agreement)

CLEOPATRA CLINICS
AL SHEIKH ZAYED
(100% ownership)

CLEOPATRA CLINICS
NEW CAIRO
(100% ownership)

BEDAYA
(60% ownership)

Note: Cases served includes number of in-patients, out-patient visits and ER consultations.

Cementing Impact Today & Scaling for the Future

Performance Progression (EGP mn)

CAGR	2015-2019	2019-2022	2022-2025
Revenue	45%	13%	40%
Gross Profit	45%	12%	48%
EBITDA	41%	12%	44%
Net Profit	40%	10%	39%



Record Breaking Results for H1 2026

CHG reported consolidated revenues of EGP 4,309mn in 1H2026, a 27% increase versus 1H2025. The addition of Cleopatra El Tagamoa Hospital (CTH), which launched in late January 2026, was a key driver of this top-line growth, contributing 10% of total Group revenues. The increase also reflects the robust underlying performance across the existing hospital network. Due to the enhancement of the case mix and the implementation of a new pricing strategy at the beginning of the year, the group recorded 12% growth in gross profit reaching a margin of 34% (y-o-y).Similarly adjusted EBITDA grew 10% reaching a margin of 27%.

CHG reported a 34% y-o-y decline in net profit to EGP 342mn in the 1H2026, primarily attributable to higher G&A expenses, including the LTIP charge recorded in June, alongside higher interest expenses in a still-high interest rate environment. On a normalized basis, net profit reached EGP 482mn (-20% y-o-y), with a normalized net profit margin of 11.0%. As expansion-related costs taper off, and CTH and COH capacity matures, margins are expected to recover meaningfully, supporting a stronger profitability trajectory ahead.

H1 2026 Snapshot

EGP **4,309** mn
Consolidated revenues in H1 2026
+27% y-o-y

EGP **1,467** mn
Gross Profit in H1 2026
+12% y-o-y; 34% Margin

EGP **1,176** mn
Adjusted EBITDA[1] in H1 2026
+10 % Growth y-o-y; 27% Margin

EGP **622** mn
EBIT in H1 2026
-20% y-o-y; 14% Margin

EGP **342** mn
Net Profit in H1 2026
-34% y-o-y; 8% Margin

EGP **482** mn
Normalized Net Profit[2] in H1 2026
-20% y-o-y; 11% Margin

EGP **4,263** mn
Shareholders' Equity in H1 2026
41% ROE

1000 beds
Number of Operating Beds as of H1 2026
+200 beds as of FY27

783 k
Cases served[3] in H1 2026
+13% y-o-y

-**35** % y-o-y
Earnings per Share Growth in H1 2026
EGP 0.24

1 Adjusted EBITDA: Earnings before Interest, Tax, Depreciation and Amortization adjusted for provisions, impairments, LTIP, acquisitions expenses, pre-operating expenses and excluding contributions from other income.
2 Normalized Net Profit adds back interest expense and excludes interest income from the consolidated Income Statement.
3 Cases served includes number of in-patients, out-patient visits and ER consultations.

Fast Growing, Diversified Healthcare Services Provider

Group Revenue, EBITDA and Margins | EGP mn



67% — Hospital Services

Cleopatra Hospital Group currently offers broad hospital services across all its facilities such as inpatient services, surgical activities, Cath labs and Emergency Rooms services

EGP 2,878 mn
H1 2026 Revenues

19% — Diagnostics

CHG operates **Radiology** and **Laboratory** services **across its facilities**

EGP 823 mn
H1 2026 Revenues

7% — Outpatient Pharmacies

CHG currently operates **two pharmacies** located in its polyclinics as well as **outpatient pharmacies** across its network of hospitals

EGP 282 mn
H1 2026 Revenues

2% — Polyclinics

The Group's polyclinics, that are **strategically located at highly underserved suburban regions of Cairo**

EGP 108 mn
H1 2026 Revenues

3% — Physical Therapy and Rehabilitation

CHG currently operates Physical Therapy and Rehabilitation CoEs through **Cleopatra October Hospital**, as well as general outpatient Rehab and Physiotherapy services across its facilities

EGP 128 mn
H1 2026 Revenues

2% — IVF Fertility Solutions

Bedaya, the Group's **fertility solutions arm,** serves female and male patients and is located **in the heart of West Cairo**

EGP 91 mn
H1 2026 Revenues

Macro Environment

Growing Population & Prevalence of Lifestyle Diseases

Demographics



- Egypt's current population is 105 mn as of 2023, rising from 80 mn in 2010; a CAGR of over 2% for this period. Projections forecast Egypt's population to reach 130 mn by 2030 and 175 mn by 2050.
- As of 2024, over 50% of the Egyptian population is aged 30 or below.
- The rate of Lifestyle diseases in Egypt has been growing significantly, notably obesity and diabetes, due to its high population growth.

Common Illnesses

Breast Cancer Cases



Communicable Diseases

382,642 Cases
Acute Respiratory illness

33,863 Cases
Chicken Pox

7,521 Cases
Brucella

Lung Cancer Cases



- The major disease burden in Egypt has shifted from communicable to noncommunicable.
- The probability of premature death from cancer per year is expected to increase from 7.6% in 2015 to 8.03% in 2030.
- Liver cancer is a significant health burden in Egypt, which ranks above the 90th percentile worldwide in liver cancer incidence.
- Compounded by Egypt's rapid population growth this intensifies the pressure on healthcare systems to manage illnesses and expand medical services to meet demand.

Lifestyle Diseases

Diabetes Cases Mn (2021)



Diabetes Cases Mn (2045)



% Of Adults With Obesity



- Egypt ranks 10th globally in terms of diabetes cases and forecasted to be ranked 9th in 2045 with an 9.9 million increase in the number of cases.
- Egypt recorded the 12th highest obesity rate among adults and 3rd regionally.
- Hypertension remains a critical issue in Egypt affecting 24.9% of adults.
- The rate of Lifestyle diseases in Egypt has been growing exponentially indicating the need for Centers of Excellence that tackle this prevalence. Noticeably, these centers have been growing in numbers across the region on the back of this dominant trend.
- Given the rapid population growth, these health issues are expected to place an even greater strain on Egypt's healthcare infrastructure, highlighting the critical need for the expansion of healthcare services to accommodate a growing and increasingly vulnerable population.

Egypt’s Healthcare Market Structure

Hospitals by Governorate and Geographical Disparities



- Healthcare facilities are highly concentrated in Cairo, Alexandria, Daqahleya & Giza which together represent 45.1% of the total number of beds and 46.3% of hospitals in Egypt.
- With the exceptions of South Sinai and Cairo, all governorates fall below the global average of 2.9 beds per 1,000 population; while several governorates fall below the national average of 1.3.

Medical Services in the Region



Number of Medical Faculties



- Doctor/1,000 population ratio for Egypt is higher than both MENA and GCC averages. While for nurses it is on par with the MENA ratio.
- Beds/1,000 population in Egypt significantly lags MENA and GCC countries requiring significant investment to catch up with regional benchmarks.
- Investments in healthcare infrastructure, with an aim for comprehensive and technology driven healthcare provision, will be key for Egypt’s healthcare sector development in the coming years.
- 17 Medical faculties have been launched in Egypt between 2017 and 2023 - indicating a skilled labor inflow to the industry in the near future.

Market Segmentation



Average Number of Beds per Hospital Type



- The parastatal sector, although contributing the fewest hospitals to the healthcare system, has the highest average number of beds, with 206 beds per hospital.
- In contrast, the private sector, which operates the majority of hospitals (63% of the total), remains highly fragmented, with an average of only 31 beds per hospital. This fragmentation presents an opportunity for CHG to consolidate the industry.

Sources: World Bank, IMF, CAPMAS, Colliers Consulting

Healthcare Investments in Egypt

Private Sector as a % of total Healthcare Expenditure (2023)



Government Spending



- Egypt's House of Representatives approved budget plan for fiscal year (FY) 2024/2025 allocates EGP 18.4 billion for healthcare subsidies, EGP 2.4 billion for comprehensive health insurance, and EGP 26.7 billion for health initiatives, medicine, and supplies.
- Between 2015 and 2019, the private healthcare sector saw a 1.5x increase in total investments, reaching EGP 9.3 billion in 2018-2019.
- Additionally, mergers and acquisitions within the healthcare sector, particularly in 2020 and 2021, reflect the increasing appetite for investment in the industry.

Public Private Partnership Schemes

Lease Agreements	Often used in healthcare (e.g., **Cleopatra El Tagamoa Hospital by CHG**), where the private entity leases a facility and shares revenue with the public or private owner.
Management Agreements	Used in both healthcare services, where private companies manage operations and receive a fee in exchange.
Training Agreements	Common type of partnership in which a party provides staff training to the other.
Concession Agreements	The private entity operates public services and shares profits with the government.

Investment Outlook

- Forecasted increases in population as well as forecasted increases in many illnesses creates a growing demand for a healthcare sector that is currently underserved.
- Both Public and Private Sectors have redirected resources towards tackling this issue and providing better access to healthcare.
- The Government has launched PPP schemes as a more cost-efficient way for all players to develop the sector, with each party bringing its own capabilities to ensure a high quality of services.
- Investments in healthcare infrastructure, with an aim for comprehensive and technology driven healthcare provision, will be key for Egypt's healthcare sector development in the coming years.
- Egypt requires approximately 38,000 new beds (based on Egypt's ratio 1.3 beds/1,000 population) resulting in an estimated investment of USD 8-13 billion to fill in the growing demand gap.
- The Growth of insurance is driven by an expanding middle-class population that demands quality private healthcare services.

Sources: World Bank, IMF, CAPMAS, Colliers Consulting, Arab Finance, Enterprise News

Competitive Advantages

A leading healthcare services platform with sustainable competitive advantages

CHG was a pioneering force in Egypt's private healthcare sector, recognizing its potential early on. The Group introduced an innovative 360-degree integrated management system, ***focused on delivering quality patient care and safety outcomes***. This holistic approach positions CHG as the preferred healthcare provider for both commercial and private patients in Egypt.

Capital Resources

- Only Healthcare Group of Facilities that is publicly listed on EGX
- Institutional Backing & Strategic Partnerships

- **Consolidated operating cashflow CAGR of c.40% since listing to FY23**

- **Key partner** in the Egypt's 2030 **Universal Healthcare Initiative**
- **Institutional dominated** shareholding structure

Innovation

- State of the art equipment & infrastructure
- Centers of Excellence that capture entire treatment journeys & focused on delivering quality patient care and safety of outcomes

- **Growing roaster** of fully integrated **Centers of Excellence (CoEs)** across **high demand specializations**

- CHG introduced **the first robotic surgical unit**, branded as **RoboSurge**, in a private hospital group in Egypt.

Economies of Scale

- Largest patient base at a private healthcare provider, with a growing network across Greater Cairo
- Market bargaining power

- Group serves **over 1.4mn cases and conducts over 43k surgical procedures** on an annual basis

- CHG is **the largest private sector medical procurer of volumes** across the sector's suppliers.

Integration

- Integrated Group of facilities that enable cross asset functionality
- Strong ability for synergy and efficiency extractions as the Group grows

- CHG is the only **fully integrated group of facilities** in Egypt by virtue of its developed **HIS/ERP system, Clinysis**.

- **Integrated supply chain** enabling **profitability margin expansions**

Robust Business Model

- Inorganic Growth: Synergistic Bolt-on acquisitions & Asset Light models
- Organic Growth: Consistent service offering expansions capturing entire treatment cycles

- CHG manages **1000 beds on the back of strategic M&A** activity since FY14 to FY25, and c. **200 beds anticipated by FY26 via management contracts**

- **Capacity optimization** across the Group's facilities coupled with **ramping up CoEs** that feed CHG with a **growing & refined patient base**

Leadership & Governance

- Institutionalized healthcare provider with a distinguished Board of Directors
- Experienced centralized management team that fosters sustainable growth

- **A centralized recruitment team** overseeing all CHG's employment activities & **allocating personnel effectively across the Group**

- **Scheduled development programs** across all functions of medical and non-medical practices

CHG's Centers of Excellence are built on key pillars that drive consistent, high-quality performance

Defining Centers of Excellence

Defined Scope & Sales Focus	Competitive Advantage & Differentiation	Nursing & Residents Team
Payor Recognition	Consumables Planning	Medical Equipment & Technology
Medical & Operational SoPs	Branding & Marketing Focus	Consultants
Training & Certifications	Multitude of Events & Affiliations	KPIs Tracking

A high-level perspective on the key pillars that make up CHG's definition of centers of excellence

Select Examples of CHG's Centers of Excellence

Mapping of a select set of CHG's current centers of excellence and intergroup specialization settings

Featured Medical Equipment across our Centers of Excellence and Diagnostic Services

CHG's Centers of Excellence and diagnostic services run on the newest generation of medical technology — including regional firsts across Egypt and the Middle East

ONCOLOGY
CENTER OF EXCELLENCE

1st in Middle East • AI-Driven

Linear Accelerator with AI

Varian | Vital Beam

NBH

BONE MARROW
CENTER OF EXCELLENCE

Stem Cell Separator, Apheresis Machine

TerumoBCT | Spectra Optia

CSH

CARDIOLOGY
CENTER OF EXCELLENCE

1st in Egypt

Pulsed Field Ablation

Boston Scientific (Cardiac Ablation AMPERE)

CTH

Heart-Lung Machine

LivaNova (Essenz)

CTH

Featured Medical Equipment across our Centers of Excellence and Diagnostic Services

CHG's Centers of Excellence and diagnostic services run on the newest generation of medical technology — including regional firsts across Egypt and the Middle East

UROLOGY
CENTER OF EXCELLENCE



Telemanipulating System, Surgical, Minimally Invasive (Robot)

CMR | Versuis

ASH

Endoscopic Services

AI Driven

EUS Endoscope with AI

Fujy |Arrieta 850

CTH

Radiology Services

AI Driven

MRI with AI & Deep Learning

Philips (Ingenia Ambition S)

CHC

Scanning System PET CT

Siemens (Biograph Horizon)

CTH

Growth Strategy & New Business

CHG advances its strategic agenda through a clearly defined core growth strategy – Driving sustainable expansion and value creation

- Integrating the platform to achieve higher efficiencies
- Enhancing utilization and optimizing existing capacity while expanding capacities and feeder network
- Integrating Cleopatra branding, sales and marketing approach

Geographic expansion in Egypt linked to following the main payor relationships to meet their network needs

- Leveraging payor and supplier relationships
- Establish centers of excellence and achieve international accreditation
- Group-wide digital transformation

Integration and Optimization of Operations

Optimize operations and management	Standardize and improve quality
Stronger bargaining power	Attract highly qualified medical staff

Shared cost benefits	Establish Centres of Excellence
Enhance margins	Establish partnerships with leading companies

Leveraging group synergies to expand the reach of affordable quality patient care

2026 Strategy: Foundation For Sustainable Growth & Financial Strength

Deleverage & Maintain Capital Framework

- Leverage on Organic Hospitals
- Pricing to Follow Inflation Trends
- Maintain Competitive Edge

Minimum Capex

Invest minimal capex in 2026 limited to the must-have and carried forward projects in the existing facilities

Enhanced Cash Conversion Cycle

1) Higher Collection Target
2) Decrease Inventory to 50 days
3) Manage Payment Schedules

Supporting Pillars

1. **Optimize Staff Costs**
2. **Smart Inventory Management**
3. **Right Resources for Cleopatra El Tagamoa Hospital**
4. **Leverage 2024/2025 Investments/Expansions to maintain Organic Growth**
5. **Pause Standalone Expansions & Projects**

East Cairo Integration Model	Marketing Spend B2C to maintain Premium Positioning	Efficient Manpower Plan	Plan for Minimal Working Capital Requirement	Fast Ramp-up & High Utilization	Positive EBITDA in the 1st Year of Operation

Expanding West Cairo: Cleopatra October Hospital – CHG's Flagship Asset

Facility Overview

Cleopatra October Current Facility + Extension Building

- **Transformed by CHG into a world-class tertiary hospital** specialized in orthopedics, spine, rehabilitation & sports injuries (largest COEs in Egypt & MENA).
- Operates under **a 25-year revenue-share agreement**: CHG fully consolidates operations, pays only a small revenue share, with minimal CAPEX and long-term control.
- **Operations assumed Q4 2022**; positioned as a leading center for physical therapy, long-term care & rehabilitation.
- **Largest CHG facility**: standing at c.30,000 sqm.
- Currently the hospital is in the ramp up phase with a bed capacity of 80 beds**.**
- In Feb 2025, the Group signed an agreement to extend the hospital through **a Build-to-Suit agreement to add c.200 beds** to the existing hospital. This asset-light expansion is expected to increase total capacity to up to **300 beds by 2027**.
- The extension is being fully constructed and finished by the property owner, while **CHG will invest only in medical and non-medical furnishing** to ensure the hospital meets international standards.

Physical Therapy, Long Term Care and Rehabilitation

Oct: Added Operating Rooms
Nov: Pharmacy and ICU
Dec: Laboratory and Radiology

Commenced Dialysis Services
Phase 1 Renovation Complete,
Renovated Aqua Therapy Unit

Aug: Added 23 Inpatient Beds
Inaugurated Endoscopy Center

Handover of 200 beds Extension Building

Started Consolidating with CHG

Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | ••• | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | ••• | FY 2027

- Q1 2023: 36 Beds
- Q4 2023: 42 Beds
- Q4 2024: 45 Beds
- Q3 2025: 68 Beds
- Q4 2025: 80 Beds
- FY 2027: 280 Beds

Sep: Hospital license
Added Outpatient Clinics

Fully Fledged Neurology & Orthopedic CoE focused offerings

April: Expanded Physiotherapy dept.

Nov: Add 12 ICU Beds

Strengthening Presence in Underserved Regions: Cleopatra El-Tagamoa Hospital

- In line with **CHG's strategy to expand into underserved regions,** the Group **launched a top-tier hospital in East Cairo and introduced 240 new beds to the market starting end of 2025.**
- **Operates under an asset-light, 25-year revenue-share agreement,** with CHG fully consolidating operations while **paying only a small revenue share** to the property owner.

Cleopatra El Tagamoa Hospital Specifics & Key Figures

EGP **3.5 billion Investment**	**700 million+ in state-of-the-art medical technology**	**240+ Beds**
7 OR's + 2 Cardiac Cath Labs	**New Onco-Extension with 2 LINAC's**	**1 mn Patients Capacity**
2,000+ New Jobs Created (once fully operational)	**Launch Date Phase 1: FY 2025**	**Launch Date Phase 2: FY 2026**

Accelerated Ramp Up Trajectory

+ 30% Additional Bed Capacity

1st Year Positive EBITDA

c. 10% of the Group's total Revenue 1st Year

Cleopatra El-Tagamoa Hospital: Grand Inauguration with Egypt's National Leadership

The Prime Minister witnesses the inauguration of Cleopatra El-Tagamoa Hospital, a milestone in public private partnership and advanced medical care.

Entrances


CLEOPATRA EL-TAGAMOA
CLEOPATRA HOSPITALS GROUP
CHG


EMERGENCY
طوارئ

The Grand Inauguration of Cleopatra El-Tagamoa Hospital

Reception

Atrium



CHG Academy and Auditorium

The Grand Inauguration of Cleopatra El-Tagamoa Hospital

Emergency Room

Outpatient Clinics

Operating Room

Inpatient Room

Pharmacy	Dialysis
	

Dentistry

CCU

Launch of Maadi Polyclinics as a referral hub for Nile Badrawi Hospital

Description:

- A multi-specialty polyclinic facility with **30 clinics**, with diagnostics & physiotherapy services
- Launched in **February 2026**

Scope:

- Expand and increase the market share of CHG in Maadi & Mokattam areas.
- Increase the referral rates to Nile Badrawi hospital

Governance & Management Information

CHG employs best-in-class corporate governance standards that are in line with the highest international standards…

OPERATIONS

ABC

- CHG has a zero-tolerance approach to bribery and corruption with a clear anti-bribery and anti-corruption policy for all stakeholders to abide by
- CHG follows all applicable local laws and more stringent international frameworks to ensure that there are no facilitation or bribery payments made

No Referral Fees

- CHG does not pay any referral fees or kickbacks to physicians and instead has recently developed a Doctor Sales team to revolutionize the sector in Egypt
- The sales team focuses on improving the hospital service to the physician and maintains close communication - improving loyalty and engagement

Medical Council

- CHG recently launched a group-wide medical council with multiple responsibilities – including (1) ensuring that medical personnel are providing the best medical care and outcomes for their patients (2) keeping CHG at the forefront of medical research and technology across all relevant services

Audit Committee – 3 Members

- The Audit Committee oversees the Group's financial controls with emphasis on: (1) integrity of internal controls and financial reporting; (2) performance of the internal auditors and the function (3) review of audited financials and external auditor performance (4) compliance with legal and regulatory requirements

Remuneration Committee – 3 Members

- The remuneration committee has established a formal and transparent process for fixing and reviewing the remuneration for the senior executives of the Company
- The remuneration committee also reviews KPIs and achievement of the Group's targets

Quality & Medical Ethics Committee – 3 Members

- The Quality and Medical Ethics Committee reviews the quality of care provided to the patient as well as medical KPIs for the Group in line with international standards
- The committee reports to the board compliance with the Group's Quality manuals and realization of medical outcomes

BOARD COMMITTEES

… supported by a board of directors dominated by experienced independent and non-executive directors and focused on growing shareholder value…

The Group's Board of Directors provide the necessary oversight and combination of expertise to thoroughly oversee the Group's corporate governance framework, a cornerstone of the Group's long-term success and value creation

Chairman

Ahmed Badreldin

Chairman

Executive Board Member

Dr. Ahmed Ezzeldin

Executive Member & Group CEO

Care Healthcare Representation

Samia El Baroudy

Badr Alasem

Sadhak Bindal

MCI Capital Healthcare Partners Representation

Mahmoud Attalla

Hesham Gohar

Hossam Eldin Abdelwahab

Mostafa Gamal Attia

Independent Board Members

Nabil Kamhawy

Former Head of Ernst & Young Egypt

Dr. Mahmoud El Meteini

Former President of Ain Shams University

Dr. Mohamed Awad Tag El Din

Advisor to the President of Egypt for health and prevention affairs
Former Minister of Health

Tarek Kabil

Former Minister of Trade and Industry

… and led by a highly competent and ambitious management team comprised of accomplished industry veterans with vast experience in the healthcare sector

The Group is managed by a seasoned team that brings along deep industry experience to their respective positions gained in leading regional and multinational companies and hospitals

25 Years
Average Years of Experience

8 Years
Average Tenure at the Group


Dr. Ahmed Ezzeldin
Group Chief Executive Officer

Corporate Functions


Marwa El Abbasiry
Chief HR, Compliance & Legal Officer


Hassan Fikry
Chief Strategy & New Business Officer


Amr Al Ashkar
Chief Technology Officer


Tamer Salah
Chief Commercial Officer


Dr. Adel El Ansary
Chief Medical Officer


Dr. Mohamed Ibrahim
Head of Medical Council


Amr El Rashid
Chief Financial Officer


Manal Ismail
CAPEX Planning & Biomedical Eng. Executive Director


Eman Fouda
Supply Chain Executive Director


Dr. Kareem Awad
Pharma Executive Director


Osama Nosseir
Revenue Cycle Management Executive Director


Soliman El Aasser
Transformation Director


Amr Sherif
Engineering Projects Director


Dr. Ghada Barakat
Marketing Executive Director


Ola Ahmed
Internal Audit Director

Hospital Management


Dr. Hany Victor
COO East Cairo


Dr. Nanees Adel
COO Central Cairo


Dr. Hamada AbdelHamid
COO West Cairo


Dr. Ahmed Hussein
MD Cleopatra Hospital


Dr. Hossam Momtaz
MD Cairo Specialized Hospital


Dr. Saad Adel
MD Nile Badrawi Hospital


Dr. Sameh Wasfy
MD Al Katib & Bedaya Hospitals


Dr. Ahmed Qabeel
MD Al Shorouk Hospital

Note: West Cairo consists of Cleopatra October & Al Shorouk Hospitals and West Polyclinics, East Cairo consists of Cleopatra & Cleopatra El Tagamoa Hospitals and East Polyclinics, Central Cairo consists of Cairo Specialized & Nile Badrawi Hospitals

H1 2026 in Review

Our Strategy drives consistent long-term value

Cases Served	Inpatients	Outpatient Visits	Surgeries	Revenues
3 Year CAGR: **12.4%**	3 Year CAGR: **10.8%**	3 Year CAGR: **15.2%**	3 Year CAGR: **5.0%**	3 Year CAGR: **40.3%**
H1 2026: **783,451**	H1 2026: **39,588**	H1 2026: **643,906**	H1 2026: **21,049**	H1 2026: **EGP 4,309mn**
Y-o-Y Growth **13%**	Y-o-Y Growth **15%**	Y-o-Y Growth **14%**	Y-o-Y Growth **Flat**	Y-o-Y Growth **27.4%**

Note: 3 Year CAGR from FY2021 – FY2024

H1 2026 Financial Performance Overview

Q1 2026 Snapshot

- CHG sustained its top-line growth trajectory in H1 2026, generating consolidated revenues of EGP 4,309mn, representing a 27% year-on-year increase from EGP 3,382mn in 1H2025. This performance marks a continuation of the robust growth delivered throughout 2025, underpinned by the addition of Cleopatra El Tagamoa Hospital, the continued ramp-up of Cleopatra October Hospital, and strong organic growth across the Group’s facilities.
- CHG delivered a net profit margin of 8% which compares very favourably against the Group's long-term profitability benchmarks and reflect the fundamental earnings strength of the mature portfolio. On a consolidated basis, reported net profit declined to EGP 153mn from EGP 232mn, driven primarily by interest expense rising to EGP 71mn from EGP 43mn – directly reflecting the debt financing raised for CTH – and by CTH's net loss of EGP 89mn in its inaugural quarter.











1 Adjusted EBITDA: Earnings before Interest, Tax, Depreciation and Amortization adjusted for provisions, impairments, LTIP, acquisitions expenses, pre-operating expenses and excluding contributions from other income.

Core Business Driven Growth













Balance Sheet Highlights

CAPEX Profile and Cash Flow Highlights

- **Capex & CTH Transition**
  - H1 2026 capex centered on medical equipment and fit-out at Cleopatra El Tagamoa Hospital (CTH)
  - Payments under capital commitments (PUC): EGP 721.6mn vs EGP 1213mn in H1 2025
  - Decline reflects CTH's shift from construction to operational phase (2025 figure included bulk of construction spend)
- **Net Debt Position (as of June 2026)**
  - Net financial debt: EGP 3.53bn — 18% higher than FY2025
  - Breakdown: EGP 2.67bn non-current borrowings + EGP 1,3022mn current borrowings, net of EGP 449mn cash
  - IFRS 16 lease adoption adds c. EGP 165mn (EGP 107mn non-current / EGP 58mn current) — relates to CHG's management and Polyclinic buildings
- **Leverage**
  - Net debt / annualized adjusted EBITDA: 1.50x
  - Expected to improve through 2026–2027 as CTH scales cash generation

Cash Flow Movement June YTD | EGP mn



CLHO.CA Share Performance

CHG's Price Performance | Rebased to 100

1 Month VWAP	Closing Aug 31st
17.6	17.9



Valuation Multiples

EV/EBITDA Valuation Multiples (x)



P/E Valuation Multiples (x)



Prominent Shareholding Base | as of June 2026



Key Free Float Investors

Helikon investments, Amundi Crédit Agricole Group, Coronation Trust is earned, Mazi Asset Management, Euphrates Ventures, HMG Finance, LetkoBrosseau Global Investment Management, Eaton Vance, Allianz, J.P.Morgan

Analyst Target Prices



Appendix: Financial Statements

Consolidated Income Statement

Income Statement | EGP mn	1H2025	1H2026	% Change
Revenues	3382.1	4309.2	*27.4%*
Cost of sales	(2072.8)	(2842.5)	*37.1%*
Gross profit	**1309.4**	**1466.7**	***12%***
Gross Profit Margin	*38.7%*	*34%*	
General & administrative expenses	(519.9)	(828.1)	*59.3%*
Cost of acquisition activities	(0.3)	0.0	*-100.0%*
Provisions	(17.9)	(21)	*17.4%*
Other income	9.4	4.1	*-56%*
Intangible Assets Write Off	-	-	
Discontinued Operations	-	-	
EBIT	**780.7**	**621.7**	***-20.4%***
EBIT Margin	*23.1%*	*14.4%*	
Interest income	28.0	16.3	*-41.8%*
Interest expense	(104.5)	(148.5)	*-42.2%*
Profit before tax	**704.3**	**489.5**	***-30.5%***
PBT Margin	*20.8%*	*11.4%*	
Income tax	(174.3)	(160)	*-8.5%*
Deferred tax	(8.5)	12.5	*-248.2%*
Net profit after tax	**521.5**	**342**	***-34.4%***
Net Profit Margin	*15.4%*	*7.9%*	
Distributed as follows:			
Shareholders of the company	451	270.7	*-40%*
Minority rights	70.6	71.3	*1.1%*
Profit for the period	**521.5**	**342**	***-34.4%***

Income Statement | EGP mn	1H2025	1H2026	% Change
Net Profit	521.5	342	*-34.4%*
Other comprehensive income	0.0	0.0	
Total comprehensive income for the year	**521.5**	**342**	***-34.4%***
Total comprehensive income attributable to:			
Owners of the company	451	270.7	*-40%*
Non-controlling interest	70.6	71.3	*1.1%*
Total comprehensive income for the year	**521.5**	**342**	***-34.4%***

Consolidated Balance Sheet

Balance Sheet | EGP mn	31 December 2025	30 June 2026
Non-current assets		
Fixed assets	7,072.9	7,637.4
Intangible assets	403.2	402.1
Right of use	132.9	118.6
Revenue Share Down Payment	250.3	239.4
Investment in associates	18.6	18.6
Total non-current assets	**7,877.9**	**8,416.1**
Current assets		
Inventory	281.3	476.7
Accounts receivables	1,241.5	1,554.6
Other receivables and debit balances	272.5	261.8
Due from related parties	20.5	35.5
Treasury bills	-	-
Cash	547.5	448.6
Total current assets	**2,363.3**	**2,777.2**
Total assets	**10,241.3**	**11,193.3**
Equity		
Share capital	724.7	724.7
Treasury Shares	-	-
Reserves	159.9	187.6
Retained earnings	2,705.0	2,803.9
Long term incentive plan	32.7	66.7
Equity attributable to the parent company	**3,622.3**	**3,782.9**
Non-controlling interest	418.0	480.1
Total equity	**4,040.4**	**4,263.0**
Non-current liabilities		
Non-current portion of borrowings	2,684.7	2,567.8
Creditors and other credit balances - non-current portion	-	-
Non-current portion of lease liability	122.2	107.1
Deferred tax liabilities	83.6	71.1
Total non-current liabilities	**2,890.6**	**2,746.0**
Current liabilities		
Provisions	81.4	74.5
Creditors and other credit balances	1,932.4	2,406.7
Current Portion of Long-term incentive plan	74.0	241.9
Current Portion of Borrowings	842.4	1244.1
Current portion of lease liability	53.4	58.0
Other Liabilities	42.5	42.5
Current income tax	284.2	116.6
Total current liabilities	**3,310.3**	**4,184.3**
Total liabilities	**6,200.9**	**6,930.3**
Total liabilities & shareholders' equity	**10,241.3**	**11,193.3**

Consolidated Cash Flow Statement

Cash Flow Statement | EGP	31 June 2025	30 June 2026
<u>**Cash flow from operating activities:**</u>		
Profit before tax	383.1	270.3
<u>Adjustments for:</u>		
Depreciation	58.7	128.6
Amortization of intangible assets	2.5	0.5
Allowance for impairment of current assets	7.8	12
Provision	3.6	11.4
Capital gain/Loss	(1.0)	-
Credit / Debit Interest	32.5	63.2
Changes in current tax liability	(239.5)	(327.6)
Loss / Gain in Investments in subsidiaries	-	-
Share-based payments financial liabilities	30.0	163.5
Operating profits before changes in assets and liabilities	**277.7**	**321.9**
<u>Changes in working capital:</u>		
Changes in Inventories	41.9	(159.2)
Change in trade receivables, debtors and other debit balances	(114.1)	(113.8)
Changes in Due from related parties	-	(15)
Change in trade and other payables	(81.5)	215.2
Change in lease	11.4	(5.4)
Net cash flows generated from operating activities	**135.5**	**243.7**
<u>**Cash flow from investment activities:**</u>		
Proceeds from sale of fixed assets	1.5	1.6
Fixed assets purchased	(18.7)	(75.5)
PUC purchased	(605.5)	(300.7)
Fixed assets suppliers		72.7
Credit Interest Collected	12.4	14.3
Net cash flows used in investing activities	**(610.3)**	**(287.5)**
<u>**Cash flow from financing activities:**</u>		
Treasury Shares		
Dividends paid out	(146.3)	(143.4)
Cash Proceed from Overdraft	432.8	514.8
Cash Paid to Overdraft	(435.7)	(419.4)
Interest paid	(52.3)	(185.5)
Receipts from borrowings	483.7	9.4
Repayment of Borrowings	(16.5)	(36.1)
Net cash flow from financing activities	**265.7**	**(260.3)**
Net change in cash & cash equivalents during the year	**(209.2)**	**(304.2)**
Cash and cash equivalents at the beginning of the year	700.7	759.5
Cash & cash equivalents at the end of the year	**491.5**	**455.3**

Appendix: Photo Library

Cleopatra Hospital


CHG
CLEOPATRA HOSPITALS
CAIRO SPECIALIZED HOSPITAL
العيادات الخارجية
OUTPATIENT CLINICS
CHG
GAHAR

Nile Badrawi Hospital

Al Shorouk Hospital


CLEOPATRA OCTOBER
CLEOPATRA HOSPITALS GROUP
HAVEN HOSPITAL
CHG
كليوباترا أكتوبر
مجموعة مستشفيات كليوباترا
HAVEN

Cleopatra El Tagamoa Hospital

El Katib Hospital


HOSPITAL
مستشفى


CHG
صيدلية
د/ كريم عواض علي
مدخل العيادات


CLEOPATRA CLINICS
عيادات كليوباترا
PHARMACY
صيدلية
د/ كريم عواض علي
مدخل العيادات
FALCON GROUP

Cleopatra Clinics (West Cairo)

Cleopatra Clinics (Maadi)


AL SHOROUK CLINICS
CHG
PHARMACY
CHG

Cleopatra Clinics (Suez Governorate)

Cleopatra Clinics (Pyramids Clinic)



CLEOPATRA HOSPITALS GROUP

CHG

Thank you

INVESTOR RELATIONS CONTACTS

Email: ir@cleohc.com
Website: https://www.cleopatrahospitals.com/en/investors/

SHAREHOLDER INFORMATION

EGX: CLHO.CA
Listed: June 2016
Shares Outstanding: 1.4 billion